Azitra Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Branford, Connecticut and currently employs 12 full-time employees. The company went IPO on 2023-06-16. Azitra, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
Follow-Up Questions
Who is the CEO of Azitra Inc?
Mr. Francisco Salva is the President of Azitra Inc, joining the firm since 2021.
What is the price performance of AZTR stock?
The current price of AZTR is $0.7638, it has increased 0.9% in the last trading day.
What are the primary business themes or industries for Azitra Inc?
Azitra Inc belongs to Biotechnology industry and the sector is Health Care
What is Azitra Inc market cap?
Azitra Inc's current market cap is $2.6M
Is Azitra Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Azitra Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
